OHIO HEMATOPOIETIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM (EIN 311340154) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1992

Legal Domicile

Principal Officer

MATT KALAYCIO

Phone

2164449100

Tax Period

2023-01-01 to 2023-12-31

OHIO HEMATOPOIETIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM, founded in 1992, is a micro nonprofit in the Diseases & Disorders sector that reported $99K in total revenue in fiscal year 2023. Revenue decreased 5% compared to the prior year. Expenses of $131K exceeded revenue, resulting in a 32% operating deficit.

Mission

TO ENSURE ALL OHIO RESIDENTS HAVE ACCESS TO QUALITY CARE FOR HEMATOLOGIC MALIGNANCIES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $89,265

Program Service Revenue $0

Investment Income $62

Other Revenue $10,050

TOTAL REVENUE $99,377

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $123,413

Other Expenses $131,258

TOTAL EXPENSES $131,258

Year-over-Year Comparison

	2023	2022	Change
Revenue	$99,377	$105,149	-0.1%
Expenses	$131,258	$82,574	+0.6%
Net Income	$-31,881	$22,575	-2.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JEFFREY AULETTA	BOARD MEMBER	N/A	Director	$0	$0	$0
MATT KALAYCIO	BOARD CHAIRM	N/A	Director	$0	$0	$0
BERNI MCQUIGG	BOARD TREASU	N/A	Director	$0	$0	$0
JAMES ESSELL MD	BOARD MEMBER	N/A	Director	$0	$0	$0
STEVEN KUERBITZ MD	BOARD MEMBER	N/A	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$99,377	$131,258	$315,778	$-31,881
2022	$105,149	$82,574	$330,785	$22,575
2021	$79,026	$72,060	$268,795	$6,966
2020	$76,902	$82,852	$510,484	$-5,950
2019	$106,798	$102,793	$494,686	$4,005
2018	$102,574	$83,763	$424,945	$18,811

OHIO HEMATOPOIETIC TRANSPLANT AND CELLULAR THERAPY CONSORTIUM